Correction: Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients | Journal of Hematology & Oncology

CellAction, Center for Cancer Immunotherapy, Institut Curie, Suresnes, France

Marion Alcantara

Clinical Hematology Unit, Institut Curie, Saint-Cloud, 92210, France

Marion Alcantara & Carole Soussain

Department of Biostatistics, Institut Curie, Saint-Cloud, 92210, France

Marion Chevrier

Department of Clinical Hematology and INSERM U1245, Centre Henri Becquerel, Rouen, France

Fabrice Jardin

Service d’Hématologie, Institut Bergonié, Bordeaux, France

Anna Schmitt

Neurooncology Department, Assistance Publique – Hôpitaux de Paris (APHP), Sorbonne Université, IHU, ICM, Groupe Hospitalier Pitié-Salpêtrière, Paris, France

Caroline Houillier & Khê Hoang-Xuan

Hematology, Institut Universitaire du Cancer de Toulouse Oncopôle, Toulouse, France

Lucie Oberic

AP-HM, Service de Neuro-Oncologie, CHU de la Timone, Aix-Marseille Université, CNRS, INP, Marseille Cedex, France

Olivier Chinot

Univ. Lille, CHU Lille, ULR 7365 – GRITA – Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, F-59000, France

Franck Morschhauser

Service d’Onco-hématologie, Centre Hospitalier Simone Veil, Cannes, France

Frédéric Peyrade

Department of Hematology, University Hospital of Rennes, UMR U1236, INSERM, University of Rennes, French Blood Establishment, Rennes, France

Roch Houot

Department of Hematology, Hôpital Lyon Sud, Claude Bernard Lyon 1 University, Pierre- Bénite, France

Hervé Ghesquieres

Center for Cancer Immunotherapy, Institut Curie, PSL Research University, INSERM U932, Paris, 75005, France

Carole Soussain